Khush Kiran K, Valantine Hannah A
Stanford University School of Medicine, Division of Cardiovascular Medicine, Stanford, CA 94305, USA.
Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21. doi: 10.1517/14728210902791605.
Heart transplantation is a well-established therapeutic option for many patients with end-stage heart disease. A major challenge in heart transplantation today is providing effective immunosuppression to prevent graft rejection while minimizing the many adverse effects of currently available therapies.
To systematically review current immunosuppressive treatment strategies after heart transplantation and to review emerging drugs in various stages of development.
A comprehensive literature review was performed using the online PubMed and Pharmaprojects databases.
RESULTS/CONCLUSIONS: This article gives an overview of the immunosuppressive agents in current use, with a detailed review of emerging drugs with novel therapeutic targets.
心脏移植是许多终末期心脏病患者公认的治疗选择。当今心脏移植的一个主要挑战是提供有效的免疫抑制,以防止移植物排斥,同时将现有疗法的诸多不良反应降至最低。
系统评价心脏移植后当前的免疫抑制治疗策略,并综述处于不同研发阶段的新型药物。
使用在线PubMed和Pharmaprojects数据库进行全面的文献综述。
结果/结论:本文概述了目前使用的免疫抑制剂,并详细综述了具有新型治疗靶点的新型药物。